Advanced Search

 

Study ID Status Title Patient Level Data
SAS30039 Completed A 12-week, multi-centre, randomised, double-blind, parallel-group study to compare the efficacy and tolerability of salmeterol/fluticasone propionate combination (SERETIDE™/VIANI™/ADVAIR™) 50/250μg twice-daily with fluticasone propionate 250μg twice-daily, all via the DISKUS®/ACCUHALER® as initial maintenance therapy in moderate persistent asthma. Study Listed on ClinicalStudyDataRequest.com
SAS30040 Completed A 12-week, randomised, double-blind, parallel-group study to compare the efficacy and tolerability ofsalmeterol/fluticasone propionate combination 50/100mcg twice daily with fluticasone propionate 250mcg twice daily, all via theDISKUS™/ACCUHALER™ on maintaining asthma control in moderate persistent asthmatic subjects whose symptomshave been well-controlled following an initial maintenance therapy with salmeterol/fluticasone propionate 50/250mcgcombination twice-daily for 12 weeks Study Listed on ClinicalStudyDataRequest.com
SAS40002 Completed A Randomised, Double-Blind, Double-Dummy, Parallel-Group Comparison of Seretide. Diskus/Accuhaler. 250/50 mg bid with Budesonide 800 mg bid plus Formoterol 12.0 mg bid (both via Breath-Actuated Dry Powder Inhaler) in Adolescent and Adult Moderate-Severe Asthmatics
SAS40006 Completed A Randomised, Double-Blind, Double-Dummy, Parallel-Group Comparison of Seretide DISKUS/ACCUHALER (50/250?g Strength) b.i.d. with Budesonide 800?g b.i.d. in Adolescents and Adults with Reversible Airways Obstruction
SAS40007 Completed A Randomised, Double-Blind, Double-Dummy, Parallel-Group Comparison of SERETIDE DISKUS/ACCUHALER (50/100?g Strength) twice daily (bid) with Budesonide 400?g bid in Adolescents and Adults with Reversible Airways Obstruction
SAS40009 Completed A multi-centre, randomised, double-blind, parallel group comparison of the salmeterol/ fluticasone propionate combination product (50/250µg) via Diskus twice daily versus fluticasone propionate (500µg) via Diskus twice daily in patients with moderate asthma (SAS 40009 local German study)
SAS40011 Completed Efficacy and Safety of salmeterol/fluticasone propionate (VIANI®) 50/250µg twice daily via Diskus in patients with mild to moderate asthma
SAS40013 Completed Can the serum level of eosinophil cationic protein (ECP) give directions for the choice between increasing the dose of fluticasone propionate or the addition of salmeterol in patients with symptomatic asthma?
SAS40014 Completed A multi-centre study examining the use of salmeterol xinafoate / fluticasone propionate via Diskus in relation to controlling asthma in moderate to severe patients: identifying risk factors contributing to an exacerbation of asthma and modification of treatment during exacerbations.
SAS40015 Completed A multicentre, randomised, double-blind, double-dummy, parallel-group, 12-week, active control comparison of the salmeterol/fluticasone propionate combination product (50/100mcg strength) bd via the DISKUS/ACCUHALERinhaler with …
SAS40018 Completed A Multi-Center, Randomized, Double-Blind, Double Dummy, Parallel-Group, 12 Week Active Control Comparison of Salmeterol/Fluticasone Propionate Combination Product (50/100mcg BID) via the DISKUS inhaler with Fluticasone Propionate (100mcg BID) via the DISKUS plus Oral Montelukast (10mg QD) in Adu ...
SAS40019 Completed A randomised, double blind, parallel group comparison of the effect of the salmeterol/fluticasone propionate combination product (50/250 mcg strength) bd via the Diskus inhaler with placebo bd via the Diskus inhaler in young adults who are in clinical remission of allergic asthma
SAS40020 Completed A Randomized, Double-Blind, Double-Dummy, Parallel Group, 12-Week Comparative Trial of Salmeterol/Fluticasone Propionate Combination Product 50/100mcg Twice Daily Via the DISKUS® Inhaler Versus Oral Montelukast 10mg Once Daily in Adolescents and Adults with Persistent Asthma Study Listed on ClinicalStudyDataRequest.com
SAS40021 Completed A Randomized, Double-Blind, Double-Dummy, Parallel Group, 12-Week Comparative Trial of Salmeterol/Fluticasone Propionate Combination Product 50/100mcg Twice Daily Via the DISKUS® Inhaler Versus Oral Montelukast 10mg Once Daily in Adolescents and Adults with Persistent Asthma Study Listed on ClinicalStudyDataRequest.com
SAS40023 Completed A multi-centre, prospective study of Viani 50/250µg twice daily via Diskus in patients with mild to moderate asthma Viani and Diskus are registered trademarks of the GlaxoSmithKline group of companies.
SAS40024 Completed A Randomized, Double-Blind, Parallel-Group Study Evaluating the Protective Effects of the Fluticasone Propionate/Salmeterol Combination Product (FSC, 100/50mcg BID via DISKUS) Against Bronchospasms Induced by Activity as Measured by Exercise Challenge Testing in Adolescent and Adult Subjects who Require Chronic Inhaled Corticosteroid Therapy for the Treatment of Persistent Asthma Study Listed on ClinicalStudyDataRequest.com
SAS40025 Completed A Randomized, Double-Blind, Parallel-Group Study Evaluating the Protective Effects of the Fluticasone Propionate/Salmeterol Combination Product (FSC 250/50mcg BID via DISKUS) Against Bronchospasms Induced by Activity as Measured by Exercise Challenge Testing in Adolescent and Adult Subjects who Require Chronic Inhaled Corticosteroid Therapy for the Treatment of Persistent Asthma Study Listed on ClinicalStudyDataRequest.com
SAS40026 Completed A Randomized, Double-Blind, Parallel Group, Comparative Trial of Salmeterol/Fluticasone Propionate Combination Product 50/100mcg twice daily Diskus Versus Fluticasone Propinate 250 mcg twice daily Diskus in Adolescents and Adults With Moderate To Persistent Asthma Study Listed on ClinicalStudyDataRequest.com
SAS40027 Completed A Randomized, Double-Blind, Parallel Group, Comparative Trial of Salmeterol/Fluticasone Propionate Combination Product 50/100mcg twice daily Diskus Fluticasone Propinate 250 mcg twice daily Diskus In Adolescents and Adults With Moderate to Persistent Asthma Study Listed on ClinicalStudyDataRequest.com
SAS40028 Completed An Open-Label, 12-Week Study to Evaluate the Effects of a Corticosteroid-Sparing Dose of Salmeterol/Fluticasone Propionate Combination Product 50/100mcg twice daily Via the DISKUS Inhaler on Airway Inflammation, Airway Remodeling, and Bronchial Hyperresponsiveness in Adults with Persistent Asthma Study Listed on ClinicalStudyDataRequest.com
SAS40030 Completed A study to investigate switching from usual therapy to the salmeterol/ fluticasone (50/500 mcg) combination Diskus, followed by a reduction of inhaled steroid dosage in patients with moderate to severe asthma
SAS40032 Completed A randomised, parallel-group study of Viani (Salmeterol 50 mcg plus Fluticasone 250 mcg b.i.d.) inhaled from the Diskus® inhaler compared to Budesonide (800-1600 mcg) inhaled from Turbuhaler® plus a long-acting inhaled beta-2-agonist, in subjects with asthma
SAS40036 Completed A multicenter, randomized, double-blind, double-dummy, parallel group, 16-week comparison of asthma control in adolescent and adults receiving either fluticasone propionate/salmeterol Diskus combination product 100/50mcg twice daily, fluticasone propionate Diskus 100mcg twice daily, salmeterol xinafoate 50mcg twice daily, or oral montelukast 10mg every day Study Listed on ClinicalStudyDataRequest.com
SAS40037 Completed A multicenter, randomized, double-blind, double-dummy, parallel group, 16-week comparison of asthma control in adolescents and adults receiving either fluticasone propionate/salmeterol Diskus combination product 100/50mcg twice daily, fluticasone propionate Diskus 100mcg twice daily, salmeterol xinafoate 50mcg twice daily, or oral montelukast 10mg every day Study Listed on ClinicalStudyDataRequest.com
SAS40039 Completed Fluticasone propionate 250 µg plus salmeterol 50 µg (Seretide 50/250 µg bd) combined in a single inhaler (Diskus) in symptomatic patients with mild to moderate asthma previously not treated by maintenance therapy with inhaled corticosteroids and/or long acting beta agonists in adults and childre ...

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.